Germ cell tumors (GCTs) account for 95% of testicular cancers. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the incidence of testicular GCTs has been increasing in the past 2 decades. Testicular GCTs are classified into 2 broad groups—pure seminoma and nonseminoma—which are treated differently. Pure seminomas, unlike nonseminomas, are more likely to be localized to the testis at presentation. Nonseminoma is the more clinically aggressive tumor associated with elevated serum concentrations of alphafetoprotein (AFP). The diagnosis of a seminoma is restricted to pure seminoma histology and a normal serum concentration of AFP. When both seminoma and elements of a nonseminoma are present, management follows that for a nonseminoma. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma.

  • 1.

    SiegelRLMillerKDJemalA. Cancer statistics, 2015. CA Cancer J Clin2015;65:529.

  • 2.

    National Cancer Institute. SEER Stat Fact Sheets: Testis Cancer. Available at http://seer.cancer.gov/statfacts/html/testis.html. Accessed May 28 2015.

    • Search Google Scholar
    • Export Citation
  • 3.

    HuygheEMatsudaTThonneauP. Increasing incidence of testicular cancer worldwide: a review. J Urol2003;170:511.

  • 4.

    ShanmugalingamTSoultatiAChowdhuryS. Global incidence and outcome of testicular cancer. Clin Epidemiol2013;5:417427.

  • 5.

    VerhoevenRHGondosAJanssen-HeijnenML. Testicular cancer in Europe and the USA: survival still rising among older patients. Ann Oncol2013;24:508513.

    • Search Google Scholar
    • Export Citation
  • 6.

    ChiaVMQuraishiSMDevesaSS. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev2010;19:11511159.

    • Search Google Scholar
    • Export Citation
  • 7.

    BoslGJMotzerRJ. Testicular germ-cell cancer. N Engl J Med1997;337:242253.

  • 8.

    TurnbullCRahmanN. Genome-wide association studies provide new insights into the genetic basis of testicular germ-cell tumour. Int J Androl2011;34:e86-96; discussion e96–87.

    • Search Google Scholar
    • Export Citation
  • 9.

    GreeneMHKratzCPMaiPL. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer2010;17:R109121.

    • Search Google Scholar
    • Export Citation
  • 10.

    NazeerTRoJYAmatoRJ. Histologically pure seminoma with elevated alpha-fetoprotein: a clinicopathologic study of ten cases. Oncol Rep1998;5:14251429.

    • Search Google Scholar
    • Export Citation
  • 11.

    WeissbachLBussar-MaatzRMannK. The value of tumor markers in testicular seminomas. Results of a prospective multicenter study. Eur Urol1997;32:1622.

    • Search Google Scholar
    • Export Citation
  • 12.

    KimWRosenMALangerJE. US MR imaging correlation in pathologic conditions of the scrotum. Radiographics2007;27:12391253.

  • 13.

    KleinEA. Tumor markers in testis cancer. Urol Clin North Am1993;20:6773.

  • 14.

    RagniGSomiglianaERestelliL. Sperm banking and rate of assisted reproduction treatment: insights from a 15-year cryopreservation program for male cancer patients. Cancer2003;97:16241629.

    • Search Google Scholar
    • Export Citation
  • 15.

    SaitoKSuzukiKIwasakiA. Sperm cryopreservation before cancer chemotherapy helps in the emotional battle against cancer. Cancer2005;104:521524.

    • Search Google Scholar
    • Export Citation
  • 16.

    BrydoyMFossaSDKleppO. Paternity following treatment for testicular cancer. J Natl Cancer Inst2005;97:15801588.

  • 17.

    HuygheEMatsudaTDaudinM. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer2004;100:732737.

  • 18.

    GordonWJr.SiegmundKStanisicTH. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. Int J Radiat Oncol Biol Phys1997;38:8394.

    • Search Google Scholar
    • Export Citation
  • 19.

    JonesRHVaseyPA. Part I: testicular cancer--management of early disease. Lancet Oncol2003;4:730-737.

  • 20.

    FossaSDChenJSchonfeldSJ. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst2005;97:10561066.

    • Search Google Scholar
    • Export Citation
  • 21.

    International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol1997;15:594603.

    • Search Google Scholar
    • Export Citation
  • 22.

    LeibovitchLFosterRSKopeckyKKDonohueJP. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol1995;154:17591763.

    • Search Google Scholar
    • Export Citation
  • 23.

    SeeWAHoxieL. Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. J Urol1993;150:874878.

    • Search Google Scholar
    • Export Citation
  • 24.

    MeadGMFossaSDOliverRT. Randomized Trials in 2466 Patients With Stage I Seminoma: Patterns of Relapse and Follow-up. J Natl Cancer Inst2011;103:241249.

    • Search Google Scholar
    • Export Citation
  • 25.

    GrollRJWardePJewettMA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol2007;64:182197.

    • Search Google Scholar
    • Export Citation
  • 26.

    AparicioJGarcia del MuroXMarotoP. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol2003;14:867872.

    • Search Google Scholar
    • Export Citation
  • 27.

    WardePSpechtLHorwichA. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol2002;20:44484452.

    • Search Google Scholar
    • Export Citation
  • 28.

    ChungPParkerCPanzarellaT. Surveillance in stage I testicular seminoma: risk of late relapse. Can J Urol2002;9:16371640.

  • 29.

    von der MaaseHSpechtLJacobsenGK. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer1993;29A:19311934.

    • Search Google Scholar
    • Export Citation
  • 30.

    WardePGospodarowiczMKBanerjeeD. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol1997;157:17051709; discussion 1709-1710.

    • Search Google Scholar
    • Export Citation
  • 31.

    ChungPWDaugaardGTyldesleyS. Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study [abstract]. J Clin Oncol2010;28:Abstract 4535.

    • Search Google Scholar
    • Export Citation
  • 32.

    ChungPWardeP. Stage I seminoma: adjuvant treatment is effective but is it necessary?J Natl Cancer Inst2011;103:194196.

  • 33.

    KollmannsbergerCTandstadTBedardPL. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol2015;33:5157..

    • Search Google Scholar
    • Export Citation
  • 34.

    Cohn-CedermarkGStahlOTandstadTSwenoteca. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors: a review and the SWENOTECA experience. Andrology2015;3:102110.

    • Search Google Scholar
    • Export Citation
  • 35.

    OliverRTMasonMDMeadGM. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet2005;366:293300.

    • Search Google Scholar
    • Export Citation
  • 36.

    OliverRTMeadGMRustinGJ. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol2011;29:957962.

    • Search Google Scholar
    • Export Citation
  • 37.

    AparicioJGermaJRGarcia del MuroX. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol2005;23:87178723.

    • Search Google Scholar
    • Export Citation
  • 38.

    HuddartRANormanAShahidiM. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol2003;21:15131523.

    • Search Google Scholar
    • Export Citation
  • 39.

    BeardCJTravisLBChenMH. Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer2013;119:27712777.

  • 40.

    GarmezyBPagliaroLC. Choosing treatment for stage I seminoma: who should get what?Oncology (Williston Park)2009;23:753759.

  • 41.

    JonesWGFossaSDMeadGM. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol2005;23:12001208.

    • Search Google Scholar
    • Export Citation
  • 42.

    FossaSDHorwichARussellJM. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol1999;17:1146.

    • Search Google Scholar
    • Export Citation
  • 43.

    DinniwellRChanPCzarnotaG. Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys2009;74:844851.

    • Search Google Scholar
    • Export Citation
  • 44.

    McMahonCJRofskyNMPedrosaI. Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. Radiology2010;254:3146.

    • Search Google Scholar
    • Export Citation
  • 45.

    MartinJMPanzarellaTZwahlenDR. Evidence-based guidelines for following stage 1 seminoma. Cancer2007;109:22482256.

  • 46.

    SouchonRHartmannMKregeS. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol2011;187:158166.

    • Search Google Scholar
    • Export Citation
  • 47.

    AparicioJMarotoPdel MuroXG. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol2011;29:46774681.

    • Search Google Scholar
    • Export Citation
  • 48.

    DaugaardGPetersenPMRorthM. Surveillance in stage I testicular cancer. APMIS2003;111:7683; discussion 83–75.

  • 49.

    TRISST (MRC TE24) Trial of imaging and schedule in seminoma testis. Available at: http://www.ctu.mrc.ac.uk/our_research/research_areas/cancer/studies/trisst_mrc_te24/. Accessed on May 4 2015.

    • Search Google Scholar
    • Export Citation
  • 50.

    LivseyJETaylorBMobarekN. Patterns of relapse following radiotherapy for stage I seminoma of the testis: implications for follow-up. Clin Oncol (R Coll Radiol)2001;13:296300.

    • Search Google Scholar
    • Export Citation
  • 51.

    van AsNJGilbertDCMoney-KyrleJ. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer2008;98:18941902.

    • Search Google Scholar
    • Export Citation
  • 52.

    ClassenJSchmidbergerHMeisnerC. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol2003;21:11011106.

    • Search Google Scholar
    • Export Citation
  • 53.

    PattersonHNormanARMitraSS. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol2001;59:511.

    • Search Google Scholar
    • Export Citation
  • 54.

    SchmidbergerHBambergMMeisnerC. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiat Oncol Biol Phys1997;39:321326.

    • Search Google Scholar
    • Export Citation
  • 55.

    DettiBLiviLScocciantiS. Management of Stage II testicular seminoma over a period of 40 years. Urol Oncol2009;27:534538.

  • 56.

    ChooRSandlerHWardeP. Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. Can J Urol2002;9:14791485.

    • Search Google Scholar
    • Export Citation
  • 57.

    GospodarwiczMKSturgeonJFJewettMA. Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. Semin Oncol1998;25:160173.

    • Search Google Scholar
    • Export Citation
  • 58.

    DomontJMassardCPatrikidouA. A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma. Urol Oncol2011.

    • Search Google Scholar
    • Export Citation
  • 59.

    Garcia-del-MuroXMarotoPGumaJ. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol2008;26:54165421.

    • Search Google Scholar
    • Export Citation
  • 60.

    de WitRRobertsJTWilkinsonPM. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol2001;19:16291640.

    • Search Google Scholar
    • Export Citation
  • 61.

    LoehrerPJSr.JohnsonDElsonP. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol1995;13:470476.

    • Search Google Scholar
    • Export Citation
  • 62.

    SaxmanSBFinchDGoninREinhornLH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol1998;16:702706.

    • Search Google Scholar
    • Export Citation
  • 63.

    BajorinDFSarosdyMFPfisterDG. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol1993;11:598606.

    • Search Google Scholar
    • Export Citation
  • 64.

    XiaoHMazumdarMBajorinDF. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol1997;15:25532558.

    • Search Google Scholar
    • Export Citation
  • 65.

    KondaguntaGVBacikJBajorinD. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol2005;23:92909294.

    • Search Google Scholar
    • Export Citation
  • 66.

    Tjan-HeijnenVCOosterhofGOde WitRDe MulderPH. Treatment in germ cell tumours: state of the art. Eur J Surg Oncol1997;23:110117.

  • 67.

    de WitRLouwerensMde MulderPH. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer1999;83:831833.

    • Search Google Scholar
    • Export Citation
  • 68.

    BechererADe SantisMKaranikasG. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol2005;54:284288.

    • Search Google Scholar
    • Export Citation
  • 69.

    HinzSSchraderMKempkensteffenC. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol2008;179:936940; discussion 940.

    • Search Google Scholar
    • Export Citation
  • 70.

    CremeriusUWildbergerJEBorchersH. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. Urology1999;54:900904.

    • Search Google Scholar
    • Export Citation
  • 71.

    AlbersPBenderHYilmazH. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology1999;53:808811.

    • Search Google Scholar
    • Export Citation
  • 72.

    SpermonJRDe Geus-OeiLFKiemeneyLA. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int2002;89:549556.

    • Search Google Scholar
    • Export Citation
  • 73.

    De SantisMPontJ. The role of positron emission tomography in germ cell cancer. World J Urol2004;22:4146.

  • 74.

    De SantisMBechererABokemeyerC. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol2004;22:10341039.

    • Search Google Scholar
    • Export Citation
  • 75.

    EhrlichYBramesMJBeckSD. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?J Clin Oncol2010;28:531536.

    • Search Google Scholar
    • Export Citation
  • 76.

    KollmannsbergerCDaneshmandSSoA. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol2010;28:537542.

    • Search Google Scholar
    • Export Citation
  • 77.

    KondaguntaGVBacikJSheinfeldJ. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol2007;25:8590.

    • Search Google Scholar
    • Export Citation
  • 78.

    MillerKDLoehrerPJGoninREinhornLH. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol1997;15:14271431.

    • Search Google Scholar
    • Export Citation
  • 79.

    LoehrerPJSr.LauerRRothBJ. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med1988;109:540546.

    • Search Google Scholar
    • Export Citation
  • 80.

    KondaguntaGVBacikJDonadioA. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol2005;23:65496555.

    • Search Google Scholar
    • Export Citation
  • 81.

    SchmollHJJordanKHuddartR. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2010;21Suppl 5:v140146.

    • Search Google Scholar
    • Export Citation
  • 82.

    FlechonABompasEBironPDrozJP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol2002;168:19751979.

  • 83.

    HerrHWSheinfeldJPucHS. Surgery for a post-chemotherapy residual mass in seminoma. J Urol1997;157:860862.

  • 84.

    de WitMBrennerWHartmannM. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol2008;19:16191623.

    • Search Google Scholar
    • Export Citation
  • 85.

    HuddartRAO'DohertyMJPadhaniA. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22—the NCRI Testis Tumour Clinical Study Group. J Clin Oncol2007;25:30903095.

    • Search Google Scholar
    • Export Citation
  • 86.

    SheinfeldJHerrHW. Role of surgery in management of germ cell tumor. Semin Oncol1998;25:203209.

  • 87.

    CollsBMHarveyVJSkeltonL. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int1999;83:7682.

    • Search Google Scholar
    • Export Citation
  • 88.

    ReadGStenningSPCullenMH. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol1992;10:17621768.

    • Search Google Scholar
    • Export Citation
  • 89.

    SturgeonJFMooreMJKakiashviliDM. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. Eur Urol2011;59:556562.

    • Search Google Scholar
    • Export Citation
  • 90.

    ZunigaAKakiashviliDJewettMA. Surveillance in stage I nonseminomatous germ cell tumours of the testis. BJU Int2009;104:13511356.

  • 91.

    OliverRTOngJShamashJ. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology2004;63:556561.

    • Search Google Scholar
    • Export Citation
  • 92.

    de BruinMJOosterhofGODebruyneFM. Nerve-sparing retroperitoneal lymphadenectomy for low stage testicular cancer. Br J Urol1993;71:336339.

    • Search Google Scholar
    • Export Citation
  • 93.

    StephensonAJBoslGJMotzerRJ. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol2005;23:27812788.

    • Search Google Scholar
    • Export Citation
  • 94.

    BohlenDBornerMSonntagRW. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol1999;161:11481152.

    • Search Google Scholar
    • Export Citation
  • 95.

    BohlenDBurkhardFCMillsR. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol2001;165:441444.

    • Search Google Scholar
    • Export Citation
  • 96.

    ChevreauCMazerollesCSoulieM. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol2004;46:209214.

    • Search Google Scholar
    • Export Citation
  • 97.

    CullenMHStenningSPParkinsonMC. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol1996;14:11061113.

    • Search Google Scholar
    • Export Citation
  • 98.

    OliverRTRajaMAOngJGallagherCJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol1992;148:14531455.

    • Search Google Scholar
    • Export Citation
  • 99.

    PontJAlbrechtWPostnerG. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol1996;14:441448.

    • Search Google Scholar
    • Export Citation
  • 100.

    StuderUEFeyMFCalderoniA. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol1993;23:444449.

    • Search Google Scholar
    • Export Citation
  • 101.

    SharirSFosterRSDonohueJPJewettMA. What is the appropriate follow-up after treatment?Semin Urol Oncol1996;14:4553.

  • 102.

    ChevreauCMazerollesCSoulieM. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol2004;46:209214; discussion 214–215.

    • Search Google Scholar
    • Export Citation
  • 103.

    MeinardiMTGietemaJAvan der GraafWT. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol2000;18:17251732.

    • Search Google Scholar
    • Export Citation
  • 104.

    BergerCCBokemeyerCSchneiderM. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer1995;31A:22292238.

    • Search Google Scholar
    • Export Citation
  • 105.

    StrumbergDBruggeSKornMW. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol2002;13:229236.

    • Search Google Scholar
    • Export Citation
  • 106.

    BokemeyerCBergerCCKuczykMASchmollHJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol1996;14:29232932.

    • Search Google Scholar
    • Export Citation
  • 107.

    BajorinDFMotzerRJRodriguezE. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst1993;85:6062.

    • Search Google Scholar
    • Export Citation
  • 108.

    AlbersPSienerRKregeS. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol2008;26:29662972.

    • Search Google Scholar
    • Export Citation
  • 109.

    CulineSTheodoreCTerrier-LacombeMJDrozJP. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy. J Urol1996;155:12961298.

    • Search Google Scholar
    • Export Citation
  • 110.

    DavisBEHerrHWFairWRBoslGJ. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol1994;152:111113; discussion 114.

    • Search Google Scholar
    • Export Citation
  • 111.

    StephensonAJBoslGJMotzerRJ. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol2007;25:55975602.

    • Search Google Scholar
    • Export Citation
  • 112.

    WeissbachLBussar-MaatzRFlechtnerH. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol2000;37:582594.

    • Search Google Scholar
    • Export Citation
  • 113.

    DonohueJPThornhillJAFosterRS. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer1995;31A:15991604.

    • Search Google Scholar
    • Export Citation
  • 114.

    PizzocaroG. Retroperitoneal lymph node dissection in clinical stage IIA and IIB nonseminomatous germ cell tumours of the testis. Int J Androl1987;10:269275.

    • Search Google Scholar
    • Export Citation
  • 115.

    CulineSTheodoreCCourtBH. Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis. Br J Urol1997;79:258262.

    • Search Google Scholar
    • Export Citation
  • 116.

    RabbaniFSheinfeldJFarivar-MohseniH. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol2001;19:20202025.

    • Search Google Scholar
    • Export Citation
  • 117.

    StephensonAJBoslGJBajorinDF. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol2005;174:557560; discussion 560.

    • Search Google Scholar
    • Export Citation
  • 118.

    CarverBSShayeganBEggenerS. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol2007;25:43654369.

    • Search Google Scholar
    • Export Citation
  • 119.

    WilliamsSDStableinDMEinhornLH. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med1987;317:14331438.

    • Search Google Scholar
    • Export Citation
  • 120.

    SheinfeldJMotzerRJRabbaniF. Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. J Urol2003;170:11591162.

    • Search Google Scholar
    • Export Citation
  • 121.

    VogelzangNJFraleyEELangePH. Stage II nonseminomatous testicular cancer: a 10-year experience. J Clin Oncol1983;1:171178.

  • 122.

    BehniaMFosterREinhornLH. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. Eur J Cancer2000;36:472475.

    • Search Google Scholar
    • Export Citation
  • 123.

    KondaguntaGVSheinfeldJMazumdarM. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol2004;22:464467.

    • Search Google Scholar
    • Export Citation
  • 124.

    MotzerRJSheinfeldJMazumdarM. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol1995;13:27002704.

    • Search Google Scholar
    • Export Citation
  • 125.

    DonohueJPThornhillJAFosterRS. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol1995;153:8589.

    • Search Google Scholar
    • Export Citation
  • 126.

    HartlappJHWeissbachLBussar-MaatzR. Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl1987;10:277284.

  • 127.

    HorwichANormanAFisherC. Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. J Urol1994;151:7277.

  • 128.

    LogothetisCJSwansonDADexeusF. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. J Clin Oncol1987;5:906911.

    • Search Google Scholar
    • Export Citation
  • 129.

    SternbergCN. Role of primary chemotherapy in stage I and low-volume stage II nonseminomatous germ-cell testis tumors. Urol Clin North Am1993;20:93109.

    • Search Google Scholar
    • Export Citation
  • 130.

    BoslGJGellerNLBajorinD. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol1988;6:12311238.

    • Search Google Scholar
    • Export Citation
  • 131.

    WilliamsSDBirchREinhornLH. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med1987;316:14351440.

    • Search Google Scholar
    • Export Citation
  • 132.

    EinhornLHWilliamsSDLoehrerPJ. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol1989;7:387391.

    • Search Google Scholar
    • Export Citation
  • 133.

    de WitRStoterGKayeSB. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol1997;15:18371843.

    • Search Google Scholar
    • Export Citation
  • 134.

    HorwichASleijferDTFossaSD. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol1997;15:18441852.

    • Search Google Scholar
    • Export Citation
  • 135.

    JonesRHVaseyPA. Part II: testicular cancer: management of advanced disease. Lancet Oncol2003;4:738747.

  • 136.

    de WitRStoterGSleijferDT. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer1998;78:828832.

    • Search Google Scholar
    • Export Citation
  • 137.

    FrohlichMWSmallEJ. Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy. Urol Clin North Am1998;25:451459.

    • Search Google Scholar
    • Export Citation
  • 138.

    NicholsCRCatalanoPJCrawfordED. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol1998;16:12871293.

    • Search Google Scholar
    • Export Citation
  • 139.

    TonerGCPanicekDMHeelanRT. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol1990;8:16831694.

    • Search Google Scholar
    • Export Citation
  • 140.

    KuczykMMachtensSStiefCJonasU. Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT). Int J Cancer1999;83:852855.

    • Search Google Scholar
    • Export Citation
  • 141.

    HartmannJTSchmollHJKuczykMA. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol1997;8:531538.

    • Search Google Scholar
    • Export Citation
  • 142.

    MotzerRJGellerNLTanCC. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer1991;67:13051310.

    • Search Google Scholar
    • Export Citation
  • 143.

    EinhornLHWilliamsSDChamnessA. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med2007;357:340348.

    • Search Google Scholar
    • Export Citation
  • 144.

    LorchABeyerJBascoul-MolleviC. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol2010;28:49064911.

    • Search Google Scholar
    • Export Citation
  • 145.

    LoehrerPJSr.GoninRNicholsCR. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol1998;16:25002504.

    • Search Google Scholar
    • Export Citation
  • 146.

    LorchARickOWundischT. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors. J Urol2010;184:168173.

    • Search Google Scholar
    • Export Citation
  • 147.

    LorchANeubauerAHackenthalM. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann Oncol2010;21:820825.

    • Search Google Scholar
    • Export Citation
  • 148.

    AlbersPGanzAHannigE. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol2000;164:381384.

  • 149.

    KisbenedekLBodrogiISzeldeliP. Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy. Int Urol Nephrol1995;27:325329.

    • Search Google Scholar
    • Export Citation
  • 150.

    MotzerRJBoslGJ. High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J Natl Cancer Inst1992;84:17031709.

    • Search Google Scholar
    • Export Citation
  • 151.

    FeldmanDRSheinfeldJBajorinDF. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol2010;28:17061713.

    • Search Google Scholar
    • Export Citation
  • 152.

    BanielJFosterRSGoninR. Late relapse of testicular cancer. J Clin Oncol1995;13:11701176.

  • 153.

    GeorgeDWFosterRSHromasRA. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol2003;21:113122.

  • 154.

    LipphardtMEAlbersP. Late relapse of testicular cancer. World J Urol2004;22:4754.

  • 155.

    GerlAClemmCSchmellerN. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol1997;8:4147.

  • 156.

    EasthamJAWilsonTGRussellC. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology1994;43:7480.

    • Search Google Scholar
    • Export Citation
  • 157.

    WoodDPJr.HerrHWMotzerRJ. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer1992;70:23542357.

    • Search Google Scholar
    • Export Citation
  • 158.

    De GiorgiURostiGAietaM. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol2006;50:1032-1038; discussion 1038–1039.

    • Search Google Scholar
    • Export Citation
  • 159.

    KollmannsbergerCBeyerJLierschR. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol2004;22:108114.

    • Search Google Scholar
    • Export Citation
  • 160.

    PectasidesDPectasidesMFarmakisD. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol2004;15:493497.

    • Search Google Scholar
    • Export Citation
  • 161.

    BokemeyerCOechsleKHoneckerF. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol2008;19:448453.

    • Search Google Scholar
    • Export Citation
  • 162.

    EinhornLHBramesMJJuliarBWilliamsSD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol2007;25:513516.

    • Search Google Scholar
    • Export Citation
  • 163.

    MulherinBPBramesMJEinhornLH. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplants [abstract]. J Clin Oncol2011;29:Abstract 4562.

    • Search Google Scholar
    • Export Citation
  • 164.

    MillerJCEinhornLH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol1990;17:3639.

  • 165.

    FossaSDBokemeyerCGerlA. Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer1999;85:988997.

  • 166.

    HartmannJBambergMAlbersP. Multidiciplinary treatment and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumour (GCT) origin [abstract]Proc Ann Soc Clin Oncol2003;22:400:Abstract 1607.

    • Search Google Scholar
    • Export Citation
  • 167.

    BokemeyerCNowakPHauptA. Treatment of brain metastases in patients with testicular cancer. J Clin Oncol1997;15:14491454.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 394 394 37
PDF Downloads 101 101 9
EPUB Downloads 0 0 0